Loading...
•
Dec 31, 2022
Harrow Q4 2022 Earnings Report
Announced fourth quarter and year-end 2022 financial results.
Key Takeaways
Harrow announced its Q4 and year-end results, highlighting a transformational year with the FDA approval of IHEEZO™ and the expansion of their product portfolio.
IHEEZO™ received FDA approval in September 2022.
A permanent J-Code (J2403) and Transitional Pass-Through Reimbursement payment status were issued for IHEEZO™ in 2023.
The company expanded its product portfolio with branded and compounded pharmaceutical products.
Harrow divested its non-ophthalmic-related assets, becoming a pure-play ophthalmic pharmaceutical company.
Harrow
Harrow
Forward Guidance
Harrow is excited and prepared for what 2023 and beyond has in store, but the report also contains forward-looking statements that are subject to risks and uncertainties.
Challenges Ahead
- The continued impact of the COVID-19 pandemic and any future health epidemics on financial condition, liquidity and results of operations.
- Ability to make commercially available FDA-approved products and compounded formulations and technologies in a timely manner or at all.
- Market acceptance of the Company’s products and challenges related to the marketing of the Company’s products.
- Risks related to pharmacy operations.
- Ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of products.